Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Friday.

A number of other equities research analysts also recently commented on AQXP. Zacks Investment Research raised Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Thursday, August 10th. Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. Finally, BidaskClub raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $22.25.

Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 9.19% during trading on Friday, hitting $12.85. The stock had a trading volume of 230,748 shares. Aquinox Pharmaceuticals has a one year low of $9.83 and a one year high of $19.97. The firm’s market cap is $301.51 million. The stock’s 50-day moving average is $14.28 and its 200 day moving average is $14.77.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.59). Equities analysts anticipate that Aquinox Pharmaceuticals will post ($2.15) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Lowers Aquinox Pharmaceuticals, Inc. (AQXP) to Sell” was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/15/valuengine-lowers-aquinox-pharmaceuticals-inc-aqxp-to-sell.html.

A number of hedge funds have recently bought and sold shares of AQXP. Nexthera Capital LP purchased a new stake in Aquinox Pharmaceuticals during the second quarter valued at about $1,276,000. Sphera Funds Management LTD. purchased a new stake in Aquinox Pharmaceuticals during the second quarter valued at about $874,000. Vanguard Group Inc. grew its position in Aquinox Pharmaceuticals by 6.6% during the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after acquiring an additional 17,455 shares during the period. Geode Capital Management LLC grew its position in Aquinox Pharmaceuticals by 10.0% during the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after acquiring an additional 11,035 shares during the period. Finally, Investment Centers of America Inc. purchased a new stake in Aquinox Pharmaceuticals during the first quarter valued at about $172,000. 95.15% of the stock is owned by hedge funds and other institutional investors.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.